Dragana Milojkovic

Summary

Affiliation: Imperial College
Country: UK

Publications

  1. ncbi State-of-the-art in the treatment of chronic myeloid leukaemia
    Dragana Milojkovic
    Department of Haematology, The Hammersmith Hospital, London, UK
    Curr Opin Oncol 20:112-21. 2008
  2. ncbi Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy
    Amr R Ibrahim
    Department of Haematology, Imperial College London, London, UK
    Blood 116:5497-500. 2010
  3. ncbi European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
    David Marin
    Department of Haematology, Hammersmith Hospitals Trust, Imperial College London, London, United Kingdom
    Blood 112:4437-44. 2008
  4. ncbi Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
    Amr R Ibrahim
    Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Road, London, United Kingdom
    Blood 117:3733-6. 2011
  5. ncbi Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?
    David Marin
    Department of Haematology, Hammersmith Hospitals Trust, Imperial College London, London, UK
    Br J Haematol 145:373-5. 2009
  6. ncbi Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation
    Paula Garland
    Department of Hematology, Imperial College London, London, UK
    Biol Blood Marrow Transplant 17:632-9. 2011
  7. ncbi Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed
    Amr R Ibrahim
    Department of Haematology, Imperial College London, London, UK
    Haematologica 96:1779-82. 2011
  8. ncbi Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients
    Dragana Milojkovic
    Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom
    Blood 119:1838-43. 2012
  9. ncbi The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib
    Jamshid Sorouri Khorashad
    Department of Haematology, Hammersmith Hospital, Imperial College London, London, United Kingdom
    Haematologica 94:861-4. 2009
  10. ncbi EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors
    Mustafa Daghistani
    Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom
    Blood 116:6014-7. 2010

Collaborators

Detail Information

Publications24

  1. ncbi State-of-the-art in the treatment of chronic myeloid leukaemia
    Dragana Milojkovic
    Department of Haematology, The Hammersmith Hospital, London, UK
    Curr Opin Oncol 20:112-21. 2008
    ..To revise the current goals of therapy of chronic myeloid leukaemia and to incorporate the influence of the underlying chronic myeloid leukaemia biology on directing therapeutic management...
  2. ncbi Efficacy of tyrosine kinase inhibitors (TKIs) as third-line therapy in patients with chronic myeloid leukemia in chronic phase who have failed 2 prior lines of TKI therapy
    Amr R Ibrahim
    Department of Haematology, Imperial College London, London, UK
    Blood 116:5497-500. 2010
    ..Factors measurable before starting treatment with third line therapy and cytogenetic responses at 3 months can accurately predict subsequent outcome and thus guide clinical decisions...
  3. ncbi European LeukemiaNet criteria for failure or suboptimal response reliably identify patients with CML in early chronic phase treated with imatinib whose eventual outcome is poor
    David Marin
    Department of Haematology, Hammersmith Hospitals Trust, Imperial College London, London, United Kingdom
    Blood 112:4437-44. 2008
    ..In general, the LeukemiaNet criteria have useful predictive value, but a case could now be made for combining the categories "failure" and "suboptimal response."..
  4. ncbi Poor adherence is the main reason for loss of CCyR and imatinib failure for chronic myeloid leukemia patients on long-term therapy
    Amr R Ibrahim
    Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Road, London, United Kingdom
    Blood 117:3733-6. 2011
    ..In summary, we have shown that poor adherence is the principal factor contributing to the loss of cytogenetic responses and treatment failure in patients on long-term therapy...
  5. ncbi Does a rise in the BCR-ABL1 transcript level identify chronic phase CML patients responding to imatinib who have a high risk of cytogenetic relapse?
    David Marin
    Department of Haematology, Hammersmith Hospitals Trust, Imperial College London, London, UK
    Br J Haematol 145:373-5. 2009
    ..05%; increases that never exceeded 0.05% had no predictive value. The finding of a kinase domain mutation in a patient in CCyR, though rare, also predicted for loss of CCyR...
  6. ncbi Humoral and cellular immunity to primary H1N1 infection in patients with hematologic malignancies following stem cell transplantation
    Paula Garland
    Department of Hematology, Imperial College London, London, UK
    Biol Blood Marrow Transplant 17:632-9. 2011
    ..These data offer novel insights into humoral and cell-mediated immunologic responses to primary H1N1 infection...
  7. ncbi Second-generation tyrosine kinase inhibitors improve the survival of patients with chronic myeloid leukemia in whom imatinib therapy has failed
    Amr R Ibrahim
    Department of Haematology, Imperial College London, London, UK
    Haematologica 96:1779-82. 2011
    ....
  8. ncbi Responses to second-line tyrosine kinase inhibitors are durable: an intention-to-treat analysis in chronic myeloid leukemia patients
    Dragana Milojkovic
    Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom
    Blood 119:1838-43. 2012
    ..Using an intention-to-treat analysis, we have shown that the responses to second-line therapies are durable. Patients destined to fare poorly can be identified early during therapy...
  9. ncbi The level of BCR-ABL1 kinase activity before treatment does not identify chronic myeloid leukemia patients who fail to achieve a complete cytogenetic response on imatinib
    Jamshid Sorouri Khorashad
    Department of Haematology, Hammersmith Hospital, Imperial College London, London, United Kingdom
    Haematologica 94:861-4. 2009
    ....
  10. ncbi EVI-1 oncogene expression predicts survival in chronic-phase CML patients resistant to imatinib treated with second-generation tyrosine kinase inhibitors
    Mustafa Daghistani
    Department of Haematology, Imperial College London, Hammersmith Hospital, London, United Kingdom
    Blood 116:6014-7. 2010
    ..Our data suggest that screening for EVI-1 expression at the time of imatinib failure may predict for response to second-line TKI therapy and consequently aid clinical management...
  11. ncbi EBMT risk score predicts outcome of allogeneic hematopoietic stem cell transplantation in patients who have failed a previous transplantation procedure
    Katayoun Rezvani
    Department of Hematology, Imperial College, Hammersmith Hospital, Du Cane Road, London, UK
    Biol Blood Marrow Transplant 18:235-40. 2012
    ..3% for risk score 4 (intermediate, n = 42), and only 10.4% for risk scores 5-7 (high, n = 57), P = .001. We propose that the EBMT risk score can identify patients most likely to benefit from a second transplantation...
  12. ncbi Repeated vaccination is required to optimize seroprotection against H1N1 in the immunocompromised host
    Hugues de Lavallade
    Department of Haematology, Imperial College, Hammersmith Campus, 4th Floor Commonwealth Building, Du Cane Road, London W12 0NN, UK
    Haematologica 96:307-14. 2011
    ..The goal of this study was to determine the efficacy of the 2009 H1N1 vaccine in patients with hematologic malignancies...
  13. ncbi In vivo kinetics of kinase domain mutations in CML patients treated with dasatinib after failing imatinib
    Jamshid S Khorashad
    Department of Haematology, Hammersmith Hospitals Trust and Imperial College London, London, United Kingdom
    Blood 111:2378-81. 2008
    ....
  14. ncbi Optimizing patient selection for myeloablative allogeneic hematopoietic cell transplantation in chronic myeloid leukemia in chronic phase
    Jiri Pavlu
    Department of Haematology, Imperial College at Hammersmith Hospital, London, United Kingdom
    Blood 115:4018-20. 2010
    ..CML patients without comorbidities (HCT-CI score 0) with normal CRP levels (0-9 mg/L) may therefore be candidates for early allogeneic HCT after failing imatinib...
  15. ncbi Interaction between KIR3DS1 and HLA-Bw4 predicts for progression-free survival after autologous stem cell transplantation in patients with multiple myeloma
    Ian H Gabriel
    Department of Hematology, Imperial College, London, UK
    Blood 116:2033-9. 2010
    ....
  16. ncbi Adherence is the critical factor for achieving molecular responses in patients with chronic myeloid leukemia who achieve complete cytogenetic responses on imatinib
    David Marin
    Department of Haematology, Imperial College London, Hammersmith Hospital, Du Cane Rd, London W12 0NN, United Kingdom
    J Clin Oncol 28:2381-8. 2010
    ..There is a considerable variability in the level of molecular responses achieved with imatinib therapy in patients with chronic myeloid leukemia (CML). These differences could result from variable therapy adherence...
  17. ncbi Early prediction of success or failure of treatment with second-generation tyrosine kinase inhibitors in patients with chronic myeloid leukemia
    Dragana Milojkovic
    Department of Haematology, Imperial College London, Du Cane Road, London W12 0NN, United Kingdom
    Haematologica 95:224-31. 2010
    ..However, it has not yet been established which of the patients in whom imatinib treatment fails are likely to benefit from therapy with second-generation tyrosine kinase inhibitors...
  18. ncbi Technical aspects and clinical applications of measuring BCR-ABL1 transcripts number in chronic myeloid leukemia
    Letizia Foroni
    Department of Haematology, Imperial College Academic Health Science Centre, Hammersmith Campus, London, W12 ONN United Kingdom
    Am J Hematol 84:517-22. 2009
    ..The technical aspects and clinical applications of molecular monitoring will be the main focus of this article...
  19. ncbi Deletions adjacent to BCR and ABL1 breakpoints occur in a substantial minority of chronic myeloid leukemia patients with masked Philadelphia rearrangements
    Valeria A S De Melo
    Department of Haematology, Imperial College London, Hammersmith Hospital Campus, Du Cane Road, London W12 0NN, UK
    Cancer Genet Cytogenet 182:111-5. 2008
    ..1 and 22q11.2 chromosomal regions, regardless of the subsequent mechanism of chromosomal rearrangement...
  20. ncbi Finding of kinase domain mutations in patients with chronic phase chronic myeloid leukemia responding to imatinib may identify those at high risk of disease progression
    Jamshid S Khorashad
    Department of Haematology, Hammersmith Hospitals Trust, Imperial College London, Du Cane Rd, London W12 0NN, United Kingdom
    J Clin Oncol 26:4806-13. 2008
    ..Kinase domain (KD) mutations in the BCR-ABL gene are associated with resistance to imatinib in chronic myeloid leukemia (CML) but their incidence and prognostic significance in chronic phase (CP) patients without resistance are unclear...
  21. ncbi Imatinib for newly diagnosed patients with chronic myeloid leukemia: incidence of sustained responses in an intention-to-treat analysis
    Hugues de Lavallade
    Department of Haematology, Imperial College London, Du Cane Rd, London W12 0NN, United Kingdom
    J Clin Oncol 26:3358-63. 2008
    ..Here, we report our experience in treating patients at a single institution in a setting where all events were recorded...
  22. ncbi Pleural effusions in patients with chronic myeloid leukaemia treated with dasatinib may have an immune-mediated pathogenesis
    Hugues de Lavallade
    Br J Haematol 141:745-7. 2008
  23. ncbi Philadelphia-negative clonal hematopoiesis is a significant feature of dasatinib therapy for chronic myeloid leukemia
    Valeria A S De Melo
    Blood 110:3086-7. 2007
  24. ncbi Interferon-alpha or homoharringtonine as salvage treatment for chronic myeloid leukemia patients who acquire the T315I BCR-ABL mutation
    Hugues de Lavallade
    Blood 110:2779-80. 2007